Mymetics reclaims innovative intra-nasal influenza vaccine
Epalinges, Switzerland, 4 October 2011
Mymetics Corporation, a pioneer in the development of vaccines that use the human mucosal system, the body’s first line of defense, to prevent transmission of infectious diseases, announced today that it has been able to regain its innovative intra-nasal influenza vaccine from Solvay.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| 111004 Final Press release intra-nasal Flu | Download |